Product image of Nimbex (Cisatracurium Besilate) supplied by GNH India

Nimbex

Active Ingredient:
Cisatracurium Besilate
Origin:
EU

Nimbex (Cisatracurium Besilate)

Cisatracurium besilate, the active ingredient in Nimbex, is a non-depolarizing neuromuscular blocking agent presented as an injectable solution for intravenous use. It facilitates endotracheal intubation, provides muscle relaxation during surgery, and supports mechanical ventilation in intensive care settings.

GNH India supplies Nimbex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Aspen Pharma Trading Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Cisatracurium besilate, a non‑depolarizing neuromuscular blocker, is used in clinical situations requiring skeletal muscle relaxation.

  • Facilitation of endotracheal intubation: provides rapid, controlled relaxation of the airway muscles to enable safe tube placement.
  • Muscle relaxation during surgery: maintains a relaxed skeletal musculature throughout general anesthesia for optimal surgical conditions.
  • Mechanical ventilation: supports prolonged ventilation by preventing patient‑initiated breaths that could interfere with ventilator synchrony.

How It Works

  • Cisatracurium besilate acts as a competitive antagonist at nicotinic acetylcholine receptors on the motor end‑plate of skeletal muscle. By occupying the receptor without activating it, the drug blocks acetylcholine‑mediated depolarisation, preventing muscle fibre contraction and producing dose‑dependent skeletal muscle relaxation. It is eliminated primarily by Hofmann degradation, a temperature‑ and pH‑dependent non‑enzymatic process that limits systemic accumulation.

Side Effects

Cisatracurium besilate may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects

  • Redness or pain at the injection site
  • Transient flushing or warmth sensation
  • Mild hypotension
  • Bradycardia
  • Histamine release causing itching

Serious or Rare Side Effects

  • Prolonged neuromuscular blockade leading to respiratory failure
  • Anaphylactic reaction with airway edema
  • Hyperkalemia in susceptible patients

Precautions & Warnings

When using cisatracurium besilate, clinicians should observe specific safety measures to minimise risks.

  • Patient monitoring: continuous neuromuscular function monitoring is required during infusion.
  • Dose adjustment: reduce dose in patients with severe hepatic or renal impairment due to altered elimination.
  • Histamine sensitivity: avoid rapid bolus in patients with known histamine‑mediated disorders.
  • Concomitant neuromuscular blockers: avoid simultaneous use with other depolarizing agents to prevent additive blockade.
  • Pregnancy and lactation: use only if benefit outweighs potential risk, as safety data are limited.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Cisatracurium besilate can interact with other medications that affect neuromuscular transmission or histamine release.

Major Interactions (Avoid)

  • Aminoglycoside antibiotics (e.g., gentamicin): potentiate neuromuscular blockade, increasing risk of prolonged paralysis.
  • Volatile anesthetics (e.g., sevoflurane): synergistic effect on muscle relaxation, may require dose reduction.

Moderate Interactions (Monitor Closely)

  • Magnesium sulfate: enhances blockade, monitor neuromuscular function.
  • Lithium therapy: may increase sensitivity to neuromuscular blockers.
  • Calcium channel blockers: can modestly augment blockade, observe patient response.

Frequently Asked Questions

Nimbex, containing cisatracurium besilate, is used to facilitate endotracheal intubation, provide skeletal muscle relaxation during surgical procedures, and support patients who require mechanical ventilation by preventing spontaneous breathing efforts.

Cisatracurium besilate competitively blocks nicotinic acetylcholine receptors at the neuromuscular junction, stopping acetylcholine‑induced depolarisation and thereby producing controlled skeletal muscle relaxation. Its elimination occurs mainly through Hofmann degradation, a temperature‑ and pH‑dependent process.

The dose of Nimbex is determined by the prescribing clinician based on the patient’s weight, clinical condition, and desired depth of muscle relaxation. Dosing regimens are individualized and should follow institutional protocols and the product’s prescribing information.

Safety data for cisatracurium besilate in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Nimbex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Nimbex (cisatracurium) is a non‑depolarizing blocker that undergoes organ‑independent Hofmann elimination, offering predictable duration and reduced reliance on renal or hepatic function. Compared with agents like rocuronium, it may have a slightly longer onset but provides a stable profile in patients with organ impairment.

Nimbex should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain sterility and potency.

Nimbex is supplied as an injectable solution for intravenous administration. It is typically given as a bolus dose for rapid onset, followed by a continuous infusion or repeat dosing to maintain the desired level of muscle relaxation under close monitoring.

The most serious risks include prolonged neuromuscular blockade that can lead to respiratory failure, anaphylactic reactions with airway edema, and severe hypotension or bradycardia due to histamine release. Immediate monitoring and supportive measures are essential.

Nimbex is contraindicated in patients with known hypersensitivity to cisatracurium or any component of the formulation. Caution is advised in individuals with severe hepatic or renal impairment, known histamine‑mediated disorders, or those receiving other potent neuromuscular blocking agents.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.